Dr. László Czirják is Professor of Rheumatology and Medicine and Head of the Department of Immunology and Rheumatology, University of Pécs, Pécs, Hungary. His article on Scleroderma-Like Disorders is featured in Chapter 1 of the ISN's book, Voices of Scleroderma Volume 3.
Author of more than 100 scientific publications, his main field of interest is the clinical, epidemiological, and immunological aspects of scleroderma. He is also actively involved in the organization of care of scleroderma patients in his country and in Europe. Besides, his department is also involved in the treatment of patients with lupus, myositis, vasculitis and Sjogren's syndrome.
Dr. László Czirják is currently a board member of the EULAR Scleroderma Trial and Research group (EUSTAR), and vice president of the Society of the Hungarian Rheumatologists. He is also the head of the Hungarian National Board of Clinical Immunology and Allergology.
Dr. László Czirják, M.D., PhD
University of Pécs
Department of Immunology and Rheumatology, Irgalmasok u. 1. H-7621 Pécs, Hungary
Phone: 336 72 507 359
Fax: +36 72 507 359
Disorders of the Scleroderma Family: The Importance of the Differential Diagnosis.Lipodystrophy or lipoatrophy may be confused with the late stages of morphea or systemic scleroderma. There is a long list of disorders causing scleroderma-like skin changes. Consider this possibility if your particular case seems to be atypical, showing unusual symptoms or distribution of skin involvement. In atypical cases you may consider the coexistence of another disease. László Czirják. First EULAR/EUSTAR Course. (Also see Disorders Similar to Scleroderma: Localized Lipodystrophy)
Dr. László Czirják is Professor of Rheumatology and Medicine and Head of the Department of Immunology and Rheumatology, University of Pécs, Pécs, Hungary. His article on Scleroderma-Like Disorders is featured in Chapter 1 of the ISN's book, Voices of Scleroderma Volume 3. Posted 02-09-06.
Finding a Scleroderma Expert. International Scleroderma Network.
Juvenile Systemic Sclerosis: A Follow-up Study of Eight Patients. Our results suggest that in jSSc, Raynaud's phenomenon is more severe, whereas internal organ manifestations and the frequency of autoantibodies are far less pronounced than in adult-onset SSc. Also, the survival rate and final outcome of patients with jSSc appear to be better than those in patients with adult-onset SSc. PubMed, Ann N Y Acad Sci. 2005 Jun;1051:229-34. (Also see Juvenile Scleroderma)
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: